C4 Therapeutics Unveils Promising Data on CFT1946 at ESMO 2024

C4 Therapeutics Presents Insights on CFT1946 at ESMO 2024

Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity

Investor Webcast Scheduled for September 13, 2024

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company focused on targeted protein degradation, announced exciting developments surrounding their Phase 1 clinical trial of CFT1946. This novel BiDAC™ degrader targets mutant BRAF V600 solid tumors. In conjunction with the European Society for Medical Oncology (ESMO) Congress 2024, important clinical data reflecting favorable safety and anti-tumor activity was made public.

The abstract, with data up to April 12, 2024, indicates promising results. An oral presentation will take place on September 13, 2024, and will include details from 36 patients regarding their demographics, safety measures, pharmacokinetics, pharmacodynamics, and anti-tumor activities assessed by RECIST 1.1 criteria.

Details of the ESMO 2024 Presentation

Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BiDAC™ Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: September 13, 2024, 4:10 pm CEST (10:10 am ET)
Final Publication Number: 612O
Session Category: Proffered paper session 1
Session Title: Developmental therapeutics
Location: Santander Auditorium – Hall 5
Presenter: Maria Vieito, M.D., MSc (Barcelona, Spain)

Webcast for Analysts and Investors

C4T will conduct a webcast on September 13, 2024, at 12:00 pm ET to discuss the findings in detail. Participation in the webcast can be accessed via the company’s 'Events & Presentations' page on their official website. A recorded version of the webcast will be available afterward.

About C4 Therapeutics

C4 Therapeutics (C4T), a company listed on Nasdaq (CCCC), is at the forefront of bioscience, dedicated to bringing innovative, targeted therapies to market. They utilize their TORPEDO® platform to effectively strategize and enhance small-molecule medications for hard-to-treat conditions. Their proprietary medicine aims to exploit the body's natural protein recycling mechanisms to efficiently degrade harmful proteins, thus offering hope for challenging health issues like drug resistance.

Understanding CFT1946

CFT1946 is a breakthrough orally bioavailable BiDAC™ degrader that showcases strong selectivity for BRAF V600X mutations. Early preclinical findings demonstrate its effectiveness both in vivo and in vitro under various settings, especially in conditions driven by BRAF V600E mutations and resistant to standard BRAF inhibitors. This Phase 1 dose escalation study includes multiple solid tumor types – notably colorectal cancer, melanoma, and non-small cell lung cancer. Further trial details can be found in the clinical trial registry.

Frequently Asked Questions

What is C4 Therapeutics known for?

C4 Therapeutics is renowned for its innovations in targeted protein degradation science, focusing on developing therapies to treat difficult diseases.

What is CFT1946?

CFT1946 is an investigational medication that targets BRAF V600X mutations using BiDAC™ technology, showing promise in treating various solid tumors.

When will the ESMO Congress 2024 take place?

The ESMO Congress 2024 is scheduled from September 13 to 17, 2024.

How can I view the presentation from C4T?

You can view the oral presentation during the ESMO Congress directly through their official event channels or the C4T website.

Where can I get more information about the trials?

Detailed information regarding clinical trials, including CFT1946, can be accessed at www.clinicaltrials.gov.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.